ES2177781T3 - Composiciones estables de proteina-fosfolipido y metodo de preparacion - Google Patents

Composiciones estables de proteina-fosfolipido y metodo de preparacion

Info

Publication number
ES2177781T3
ES2177781T3 ES96911458T ES96911458T ES2177781T3 ES 2177781 T3 ES2177781 T3 ES 2177781T3 ES 96911458 T ES96911458 T ES 96911458T ES 96911458 T ES96911458 T ES 96911458T ES 2177781 T3 ES2177781 T3 ES 2177781T3
Authority
ES
Spain
Prior art keywords
compositions
protein
phospholipide
preparation
stable protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES96911458T
Other languages
English (en)
Inventor
David Collins
Younsik Cha
David Brems
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amgen Inc
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Application granted granted Critical
Publication of ES2177781T3 publication Critical patent/ES2177781T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/196—Thrombopoietin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S930/00—Peptide or protein sequence
    • Y10S930/01—Peptide or protein sequence
    • Y10S930/14—Lymphokine; related peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S930/00—Peptide or protein sequence
    • Y10S930/01—Peptide or protein sequence
    • Y10S930/14—Lymphokine; related peptides
    • Y10S930/145—Colony stimulating factor

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Nanotechnology (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biochemistry (AREA)
  • Medical Informatics (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

LA INVENCION SE REFIERE A COMPOSICIONES ESTABLES DE PROTEINAS Y A METODOS RELACIONADOS EN LOS QUE UNA PROTEINA CAPAZ DE HACER LA TRANSICION A ESTADO GLOBULAR FUNDIDO SE PONE EN CONTACTO CON UNA VESICULA LIPIDICA CARGADA NEGATIVAMENTE DE MODO QUE SE ESTABILIZA LA PROTEINA CONTRA LA AGREGACION, DESNATURALIZACION Y PERDIDA DE ACTIVIDAD INDUCIDAS TERMICAMENTE. EL COMPLEJO DE PROTEINA:FOSFOLIPIDO ESTABILIZA DIRECTAMENTE LA ESTRUCTURA SECUNDARIA Y TERCIARIA DE LA PROTEINA, Y LAS COMPOSICIONES SON UTILES EN FORMULACIONES DE ELEVADA TEMPERATURA Y EN NUEVOS VEHICULOS DE ADMINISTRACION.
ES96911458T 1995-03-31 1996-03-28 Composiciones estables de proteina-fosfolipido y metodo de preparacion Expired - Lifetime ES2177781T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/414,161 US5874075A (en) 1993-10-06 1995-03-31 Stable protein: phospholipid compositions and methods

Publications (1)

Publication Number Publication Date
ES2177781T3 true ES2177781T3 (es) 2002-12-16

Family

ID=23640216

Family Applications (1)

Application Number Title Priority Date Filing Date
ES96911458T Expired - Lifetime ES2177781T3 (es) 1995-03-31 1996-03-28 Composiciones estables de proteina-fosfolipido y metodo de preparacion

Country Status (23)

Country Link
US (1) US5874075A (es)
EP (1) EP0817614B1 (es)
JP (1) JP3856471B2 (es)
KR (1) KR100228415B1 (es)
CN (1) CN1241548C (es)
AT (1) ATE222096T1 (es)
BR (1) BR9607999A (es)
CA (1) CA2215534C (es)
CZ (1) CZ292788B6 (es)
DE (1) DE69623003T2 (es)
DK (1) DK0817614T3 (es)
EA (1) EA000415B1 (es)
ES (1) ES2177781T3 (es)
HU (1) HU224691B1 (es)
IL (1) IL117690A0 (es)
NO (1) NO318235B1 (es)
NZ (1) NZ306156A (es)
PT (1) PT817614E (es)
SK (1) SK283596B6 (es)
TW (1) TW400236B (es)
UA (1) UA62911C2 (es)
WO (1) WO1996029989A1 (es)
ZA (1) ZA962483B (es)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6001968A (en) 1994-08-17 1999-12-14 The Rockefeller University OB polypeptides, modified forms and compositions
US6429290B1 (en) 1994-08-17 2002-08-06 The Rockefeller University OB polypeptides, modified forms and derivatives
AU4344697A (en) * 1996-10-04 1998-04-24 Amgen, Inc. Pharmaceutical compositions containing an mpl ligand
SI0937456T1 (en) * 1998-02-23 2004-12-31 Cilag Ag International Erythropoietin liposomal dispersion
DK1656952T3 (da) 1998-10-16 2014-01-20 Biogen Idec Inc Polyalkylenglycolkonjugater af interferon beta-1A og anvendelser deraf
DK1121382T3 (da) * 1998-10-16 2006-11-13 Biogen Idec Inc Interferon-beta-fusionsproteiner og deres anvendelser
EP1214928A4 (en) * 1999-08-18 2004-03-24 Kyowa Hakko Kogyo Kk HAIR GROWTH FUNDS
PT1129720E (pt) 2000-02-29 2004-08-31 Pfizer Prod Inc Factor estimulador de colonias de granulocitos estabilizado
US6416745B1 (en) * 2001-05-03 2002-07-09 Block Drug Company, Inc. Dental composition for treating hypersensitive teeth
US7214660B2 (en) * 2001-10-10 2007-05-08 Neose Technologies, Inc. Erythropoietin: remodeling and glycoconjugation of erythropoietin
US7173003B2 (en) * 2001-10-10 2007-02-06 Neose Technologies, Inc. Granulocyte colony stimulating factor: remodeling and glycoconjugation of G-CSF
US7157277B2 (en) 2001-11-28 2007-01-02 Neose Technologies, Inc. Factor VIII remodeling and glycoconjugation of Factor VIII
EE05509B1 (et) 2002-01-18 2012-02-15 Biogen@Idec@Ma@Inc Aktiveeritud polalkleenglkoolpolmeer ja seda sisaldavad kompositsioonid
US20060193905A1 (en) * 2002-05-14 2006-08-31 University Of Louisville Research Foundation, Inc. Direct cellular energy delivery system
KR20060003862A (ko) * 2003-03-14 2006-01-11 네오스 테크놀로지스, 인크. 수용성분기폴리머 및 그 접합체
US8791070B2 (en) 2003-04-09 2014-07-29 Novo Nordisk A/S Glycopegylated factor IX
EP2055189A1 (en) 2003-04-09 2009-05-06 Neose Technologies, Inc. Glycopegylation methods and proteins/peptides produced by the methods
EP1633440B1 (en) * 2003-04-15 2008-05-14 Opperbas Holding B.V. Pharmaceutical composition comprising proteins and/or polypeptides and colloidal particles
WO2005012484A2 (en) * 2003-07-25 2005-02-10 Neose Technologies, Inc. Antibody-toxin conjugates
US20080305992A1 (en) 2003-11-24 2008-12-11 Neose Technologies, Inc. Glycopegylated erythropoietin
US8633157B2 (en) * 2003-11-24 2014-01-21 Novo Nordisk A/S Glycopegylated erythropoietin
US20060040856A1 (en) * 2003-12-03 2006-02-23 Neose Technologies, Inc. Glycopegylated factor IX
US7338933B2 (en) * 2004-01-08 2008-03-04 Neose Technologies, Inc. O-linked glycosylation of peptides
US20070081986A1 (en) * 2005-10-07 2007-04-12 Shunji Tomatsu Beta-glucuronidase with an attached short peptide of acidic amino acids
WO2006010143A2 (en) * 2004-07-13 2006-01-26 Neose Technologies, Inc. Branched peg remodeling and glycosylation of glucagon-like peptide-1 [glp-1]
WO2006031811A2 (en) * 2004-09-10 2006-03-23 Neose Technologies, Inc. Glycopegylated interferon alpha
US20080176790A1 (en) 2004-10-29 2008-07-24 Defrees Shawn Remodeling and Glycopegylation of Fibroblast Growth Factor (Fgf)
US9029331B2 (en) * 2005-01-10 2015-05-12 Novo Nordisk A/S Glycopegylated granulocyte colony stimulating factor
DE102005012457B3 (de) 2005-03-18 2006-08-31 Basf Coatings Ag Epoxid- und Silangruppen enthaltende Oligomere und Polymere, Verfahren zu ihrer Herstellung und ihre Verwendung
US20070154992A1 (en) * 2005-04-08 2007-07-05 Neose Technologies, Inc. Compositions and methods for the preparation of protease resistant human growth hormone glycosylation mutants
EP1891231A4 (en) * 2005-05-25 2011-06-22 Novo Nordisk As GLYCOPEGYLATED FACTOR IX
KR100770704B1 (ko) 2005-08-04 2007-10-29 삼성전자주식회사 픽쳐 스킵 방법 및 장치
US20070105755A1 (en) * 2005-10-26 2007-05-10 Neose Technologies, Inc. One pot desialylation and glycopegylation of therapeutic peptides
WO2007056191A2 (en) 2005-11-03 2007-05-18 Neose Technologies, Inc. Nucleotide sugar purification using membranes
ES2516694T3 (es) * 2006-07-21 2014-10-31 Ratiopharm Gmbh Glicosilación de péptidos a través de secuencias de glicosilación con unión en O
US8969532B2 (en) * 2006-10-03 2015-03-03 Novo Nordisk A/S Methods for the purification of polypeptide conjugates comprising polyalkylene oxide using hydrophobic interaction chromatography
US20100041872A1 (en) * 2006-10-04 2010-02-18 Defrees Shawn Glycerol linked pegylated sugars and glycopeptides
KR20100016160A (ko) * 2007-04-03 2010-02-12 바이오제너릭스 에이지 글리코페길화 ｇ―ｃｓｆ를 이용하는 치료 방법
EP2162535A4 (en) * 2007-06-04 2011-02-23 Novo Nordisk As O-linked glycosylation using N-acetylglucosamine transferases
WO2008154639A2 (en) * 2007-06-12 2008-12-18 Neose Technologies, Inc. Improved process for the production of nucleotide sugars
DE202008017456U1 (de) 2007-08-27 2009-08-27 Biogenerix Ag Flüssig-Formulierung von G-CSF-Konjugaten
US8207112B2 (en) * 2007-08-29 2012-06-26 Biogenerix Ag Liquid formulation of G-CSF conjugate
US7985727B1 (en) 2007-09-20 2011-07-26 Abbott Cardiovascular Systems Inc. Apo A-I mimetic peptides and methods of treatment
US7985728B1 (en) 2007-09-20 2011-07-26 Abbott Cardiovascular Systems Inc. Sustained release of Apo A-I mimetic peptides and methods of treatment
US8101565B2 (en) 2007-09-20 2012-01-24 Abbott Cardiovascular Systems Inc. Sustained release of Apo A-I mimetic peptides and methods of treatment
US8044021B2 (en) * 2007-09-20 2011-10-25 Abbott Cardiovascular Systems Inc. Sustained release of apo A-I mimetic peptides and methods of treatment
US9173890B2 (en) * 2007-09-20 2015-11-03 Abbott Cardiovascular Systems Inc. Sustained release of Apo A-I mimetic peptides and methods of treatment
CA2711503A1 (en) * 2008-01-08 2009-07-16 Biogenerix Ag Glycoconjugation of polypeptides using oligosaccharyltransferases
KR101582841B1 (ko) 2008-02-27 2016-01-11 노보 노르디스크 에이/에스 콘쥬게이트된 인자 ｖｉｉｉ 분자
EP2673296B1 (en) 2011-02-07 2018-10-24 Cerenis Therapeutics Holding SA Lipoprotein complexes and manufacturing and uses thereof
AU2012328524B2 (en) 2011-10-28 2017-05-18 Excelse Bio, Inc. Protein formulations containing amino acids
EP2819652A1 (en) 2012-02-27 2015-01-07 Epitarget As Use of a particulate immunomodulator in cancer therapy

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4515736A (en) * 1983-05-12 1985-05-07 The Regents Of The University Of California Method for encapsulating materials into liposomes
US4744989A (en) * 1984-02-08 1988-05-17 E. R. Squibb & Sons, Inc. Method of preparing liposomes and products produced thereby
US4766106A (en) * 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US4810643A (en) * 1985-08-23 1989-03-07 Kirin- Amgen Inc. Production of pluripotent granulocyte colony-stimulating factor
JPH03505576A (ja) * 1988-05-16 1991-12-05 ネクスター・フアーマシユーテイカルズ・インコーポレイテツド 有機化合物に関する改良
EP0393707B1 (en) * 1989-04-21 1994-10-26 Otsuka Pharmaceutical Co., Ltd. Bioactive compounds associated with liposomes and their use in pharmaceutical preparations
AU6428890A (en) * 1989-09-12 1991-04-18 Regents Of The University Of California, The Therapeutic peptides and proteins
JPH03127622A (ja) * 1989-10-09 1991-05-30 Green Cross Corp:The ｐＨ感受性リポソーム
US5225212A (en) * 1989-10-20 1993-07-06 Liposome Technology, Inc. Microreservoir liposome composition and method
JPH0482839A (ja) * 1990-07-20 1992-03-16 Green Cross Corp:The 蛋白質類・脂質小体複合体
JPH06247842A (ja) * 1993-02-23 1994-09-06 Green Cross Corp:The リポソーム組成物の製造方法
WO1995009611A2 (en) * 1993-10-06 1995-04-13 Amgen Inc. Stable protein: phospholipid compositions and methods

Also Published As

Publication number Publication date
UA62911C2 (en) 2004-01-15
JP3856471B2 (ja) 2006-12-13
DE69623003D1 (de) 2002-09-19
IL117690A0 (en) 1996-07-23
EP0817614B1 (en) 2002-08-14
CZ291297A3 (cs) 1999-02-17
US5874075A (en) 1999-02-23
BR9607999A (pt) 1998-06-23
AU688678B2 (en) 1998-03-12
SK126097A3 (en) 1999-06-11
KR100228415B1 (ko) 1999-11-01
HUP9801370A2 (hu) 1998-10-28
MX9707137A (es) 1997-11-29
EA199700197A1 (ru) 1998-04-30
HK1006079A1 (en) 1999-02-12
AU5434196A (en) 1996-10-16
ZA962483B (en) 1996-10-03
NO318235B1 (no) 2005-02-21
EA000415B1 (ru) 1999-06-24
HUP9801370A3 (en) 2000-10-30
SK283596B6 (sk) 2003-10-07
WO1996029989A1 (en) 1996-10-03
CA2215534A1 (en) 1996-10-03
DK0817614T3 (da) 2002-10-07
CN1150756A (zh) 1997-05-28
ATE222096T1 (de) 2002-08-15
TW400236B (en) 2000-08-01
CN1241548C (zh) 2006-02-15
HU224691B1 (hu) 2005-12-28
NZ306156A (en) 1999-02-25
JPH11502851A (ja) 1999-03-09
NO974323L (no) 1997-11-28
NO974323D0 (no) 1997-09-19
CA2215534C (en) 2003-05-20
EP0817614A1 (en) 1998-01-14
DE69623003T2 (de) 2003-03-27
PT817614E (pt) 2002-12-31
CZ292788B6 (cs) 2003-12-17

Similar Documents

Publication Publication Date Title
ES2177781T3 (es) Composiciones estables de proteina-fosfolipido y metodo de preparacion
EA199700289A1 (ru) Композиции для ухода за кожей, содержащие ретиноиды и липосомы
ES2054380T3 (es) Composiciones estables para administracion por via parenteral y metodo para su elaboracion.
EA199900715A1 (ru) Липидные комплексы и липосомы совершенно нерастворимых комплексов платины
MX173098B (es) Mejoras en figura posable con piel continua
ES2119411T5 (es) Combinaciones de proteinas y anticoagulantes tromboliticamente activos, y usos de los mismos.
SE8903583D0 (sv) Cyclosporin ophthalmic compositions
ES2077904T3 (es) Obtencion y uso de preparados estables de liposomas en forma de pequeñas particulas.
EP0785772A4 (en) LYOPHILISATE OF A LIPID COMPLEX OF WATER-INSOLUBLE CAMTOTHECINS
ES2184768T3 (es) Composiciones proteina:fosfolipido estables y metodos.
ES2042437T1 (es) Procedimiento de preparacion de una lipoproteina modificaa por incorporacion de una substancia activa lipofila.
FR2764508B1 (fr) Nouveaux vecteurs liposomaux de principes actifs
ES2041617T3 (es) Productos intermedios para agentes de quelacion con simetria prefijada y procedimiento para su preparacion.
PT928197E (pt) Utilizacao de proteinas como agentes contra doencas de natureza autoimunitaria
ES2077674T3 (es) Aumento de la produccion de proteinas en animales.
AR021466A1 (es) Nucleotidos y proteina antitrombina de la mosca de los cuernos
AR001858A1 (es) Una composición de agente diagnostica o terapéuticamente efectiva
CO4750749A1 (es) Mezclas estables de ingredientes activos incompatibles para proteccion de las plantas
ES2162986T3 (es) Derivados de mercapto-alcanoil-dipeptidos, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen.
DE59607417D1 (de) Konjugat zur behandlung von entzündungserkrankungen
DE69636172D1 (de) Herstellung von protein c in transgenen tieren
MX9207146A (es) Procedimiento para la fabricacion de una emulsion capilar que resuelve problemas de calvicie.
HN1999000195A (es) Azalidas de 13 miembros y su uso como agentes antibioticos.